Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Quicksilver Scientific Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 2 distinct art units. This distribution indicates that each of the 3 pending actions is being reviewed by a different individual, while the subject matter spans two different specialized groups.
MAEWALL, SNIGDHA is the busiest examiner for the company, currently responsible for 1 pending office action. Given that there are 3 distinct examiners for the pending actions, the workload is evenly spread. The involvement of 2 distinct art units suggests that the company's biotechnology filings are categorized into multiple technical niches within the patent office. This variety in both examiners and art units requires the company to manage separate prosecution tracks, each potentially subject to different examination nuances within the pharmaceutical sector. Practitioners should coordinate their efforts to ensure consistent arguments are presented across these different examiners and specialized units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLOMAN, NANNETTE | 1 | 60.7% | +22.8% |
| MAEWALL, SNIGDHA | 1 | 58.8% | +10.5% |
| MACH, ANDRE | 1 | 44.9% | +51.7% |
| WHEELER, THURMAN MICHAEL | 1 | 45.8% | +23.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17672894 | Microemulsion Delivery Systems for Alcohol-Soluble Species Including Nonderivatized Hormones | WHEELER, THURMAN MICHAEL | 38d overdue |
| 17707067 | Self-Microemulsifying Multi-Deliverable Systems | MACH, ANDRE | 34d |
| 19083881 | Means For Mitochondrial Performance Enhancement | HOLLOMAN, NANNETTE | — |
| 18891496 | Solid Binding Composition for Toxin Excretion Enhancement | MAEWALL, SNIGDHA | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19083881 | Means For Mitochondrial Performance Enhancement | HOLLOMAN, NANNETTE | — | §103 | Non-Final OA | — | Pending | Mar 19, 2025 |
| 18891496 | Solid Binding Composition for Toxin Excretion Enhancement | MAEWALL, SNIGDHA | — | §103DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 17707067 | Self-Microemulsifying Multi-Deliverable Systems | MACH, ANDRE | 1615 | §103 | Non-Final OA | 34d | Pending | Mar 29, 2022 |
| 17672894 | Microemulsion Delivery Systems for Alcohol-Soluble Species Including Nonderivatized Hormones | WHEELER, THURMAN MICHAEL | 1619 | §112Other | Final Rejection | 38d overdue | Pending | Feb 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial